comprehensive -WSS

comprehensive

author：focus 2025-10-03 01:03:29 - browse：7

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： AI can’t replace a physician’s gut feeling

focus

WSS

FDA approves RSV monoclonal antibody for infants, toddlers

10 reasons why health care startups fail

Investment in vaccine development is lagging, report finds

Sanofi seeks simpler, safer CRISPR sickle cell cure

Why Medicare shouldn’t cover every FDA

Startup Neumora takes a novel depression drug to Phase 3

entertainment

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

Drug repurposing or repositioning? The language matters

Listen: Wegovy in the brain & pivotal Alzheimer's data

Novavax promises a turnaround & Lilly roils the obesity market

Sanofi seeks simpler, safer CRISPR sickle cell cure

After affirmative action ruling, medical educators look to 'holistic review'

FDA approves RSV monoclonal antibody for infants, toddlers

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Merck CEO won’t testify in Senate, citing no expertise in drug prices

focus

In early work, researchers turn to CRISPR to treat Alzheimer's

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Biden tests positive for Covid

Health Care Service Corp to buy Cigna Medicare Advantage plans

FTC sues over Novant Health acquisition of two N.C. hospitals

Listen: Wegovy in the brain & pivotal Alzheimer's data

hotspot

focus

entertainment

hotspot